Kathleen T Karloff

CIK 1493763 · View on SEC EDGAR ↗

Insider

First SEC filing: July 3, 2017 · Latest: Sept. 26, 2019

On this page

Insider at

Insider transactions

0 buys (P) 0 sells (S) Net: $0 + 4 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

4 other filings hidden
Date Ticker Code Shares Price Value Owned after Δ own A/D vs now
Feb. 15, 2017 IVF S 400,000 $0.15 $60,000 11,760,000 Direct -3.29% Disposed -100.0% (price as of 2026-08-21)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II)

Options, RSUs and convertible securities reported on Form 4 Table II.

Date Ticker Security Underlying Exercise price Expiration Shares A/D
Feb. 5, 2020 IVF Stock Option Common Stock (99,112) $0.25 Feb. 5, 2030 99,112 Acquired
Oct. 29, 2019 IVF Stock Option [F1] Common Stock (962,336) $0.29 Oct. 29, 2029 962,336 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 3 holdings

Securities held when first becoming an insider, per SEC Form 3.

Date Ticker Security Shares Ownership
Sept. 26, 2019 IVF Common Stock 14,200,183 Direct
July 3, 2017 IVF INVO Bioscience Common Stock Restricted 5,622,159 Direct
July 3, 2017 IVF INVO Bioscience Common Stock 240,000 Direct

Compensation (DEF 14A)

Matched by name from proxy statements (DEF 14A) — verify against the filing.

IVF

Fiscal year Salary Bonus Stock awards Option awards Non-equity incentive Pension change Other Total
2019 $175,000 — — $351,799 — — — $526,799
2018 $120,000 — — — — — — $120,000

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.